sb 203580 has been researched along with jaw in 2 studies
| Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (jaw) | Trials (jaw) | Recent Studies (post-2010) (jaw) |
|---|---|---|---|---|---|
| 3,489 | 4 | 1,137 | 7,554 | 157 | 1,917 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Campana, WM; Hefferan, MP; Jones-Cordero, TL; Sorkin, L; Svensson, CI | 1 |
| Anderson, TJ; Brumlik, MJ; Curiel, TJ; Kious, MJ; Nkhoma, S; Patterson, TF; Siekierka, JJ; Thompson, GR | 1 |
2 other study(ies) available for sb 203580 and jaw
| Article | Year |
|---|---|
Spinal p38 mitogen-activated protein kinase mediates allodynia induced by first-degree burn in the rat.
Topics: Animals; Burns; Disease Models, Animal; Enzyme Activation; Enzyme Inhibitors; Imidazoles; Indoles; Male; Microglia; Neurons; Oligodendroglia; p38 Mitogen-Activated Protein Kinases; Pain; Phosphorylation; Pyridines; Rats; Rats, Sprague-Dawley; Spinal Cord | 2009 |
Human p38 mitogen-activated protein kinase inhibitor drugs inhibit Plasmodium falciparum replication.
Topics: Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Erythrocytes; Humans; Imidazoles; Indoles; Inhibitory Concentration 50; Mefloquine; p38 Mitogen-Activated Protein Kinases; Plasmodium falciparum; Protein Kinase Inhibitors; Pyridines | 2011 |